Long-acting antiretrovirals: a new era for the management and prevention of HIV infection
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long-acting antiretrovirals: a new era for the management and prevention of HIV infection
Authors
Keywords
-
Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2021-08-18
DOI
10.1093/jac/dkab324
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy, pharmacokinetics and safety over 48 weeks with ibalizumab-based therapy in treatment-experienced adults infected with HIV-1
- (2021) Joseph C. Gathe et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine
- (2021) Amy G. Cutrell et al. AIDS
- Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
- (2021) Daryl Hodge et al. CLINICAL PHARMACOKINETICS
- Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial
- (2021) Jean-Michel Molina et al. Lancet HIV
- Therapeutic review of cabotegravir/rilpivirine long‐acting antiretroviral injectable and implementation considerations at an HIV specialty clinic
- (2021) Zach W. Howe et al. PHARMACOTHERAPY
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
- (2020) Chloe Orkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
- (2020) Susan Swindells et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib
- (2020) Thierry Buclin et al. Frontiers in Pharmacology
- Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial
- (2020) Dirk Schürmann et al. Lancet HIV
- Comparative Clinical Pharmacokinetics a1 nd Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review
- (2020) Anthony T. Podany et al. CLINICAL PHARMACOKINETICS
- Advances in Long-Acting Agents for the Treatment of HIV Infection
- (2020) Aadia I. Rana et al. DRUGS
- A year-long extended release nanoformulated cabotegravir prodrug
- (2020) Tanmay A. Kulkarni et al. NATURE MATERIALS
- Design of a Drug-Eluting Subcutaneous Implant of the Antiretroviral Tenofovir Alafenamide Fumarate
- (2020) Solange M Simpson et al. PHARMACEUTICAL RESEARCH
- Effectiveness of vaginal microbicides in preventing HIV transmission
- (2020) Alfred Musekiwa et al. TROPICAL MEDICINE & INTERNATIONAL HEALTH
- Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs
- (2020) Dhanashree H. Surve et al. JOURNAL OF CONTROLLED RELEASE
- Understanding the Acceptability of Subdermal Implants as a Possible New HIV Prevention Method: Multi-Stage Mixed Methods Study
- (2020) Christine Tagliaferri Rael et al. JOURNAL OF MEDICAL INTERNET RESEARCH
- Clinical targeting of HIV capsid protein with a long-acting small molecule
- (2020) John O. Link et al. NATURE
- Long-acting antiretroviral therapy
- (2020) Vicente Soriano et al. NATURE MATERIALS
- Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
- (2020) Raphael J Landovitz et al. Lancet HIV
- Reasons People Living with HIV Might Prefer Oral Daily Antiretroviral Therapy, Long-Acting Formulations, or Future HIV Remission Options
- (2020) Karine Dubé et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Antibody-based strategies in HIV therapy
- (2020) Wesley D. Kufel INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
- (2020) Michael S. Saag et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Exploration into the opinions of patients with HIV, healthcare professionals and the lay public of the use of microneedles in clinical practice: highlighting the translational potential for their role in HIV infection
- (2020) Kurtis Moffatt et al. Drug Delivery and Translational Research
- Long-acting drugs and formulations for the treatment and prevention of HIV infection
- (2020) Charles Flexner et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
- (2020) Edgar T Overton et al. LANCET
- Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis
- (2020) Manjula Gunawardana et al. Frontiers in Pharmacology
- Long-acting injectable HIV therapies: the next frontier
- (2020) John Thornhill et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Antiretroviral Adherence Level Necessary for HIV Viral Suppression using Real-World Data
- (2019) Kathy K. Byrd et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Potential user interest in new long-acting contraceptives: Results from a mixed methods study in Burkina Faso and Uganda
- (2019) Rebecca L. Callahan et al. PLoS One
- Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP)
- (2019) Leah M. Johnson et al. Pharmaceutics
- Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline
- (2019) Lara Esteves Coelho et al. Lancet HIV
- Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities
- (2019) Sharon Nachman et al. Lancet HIV
- Creation of a long-acting rilpivirine prodrug nanoformulation
- (2019) James R. Hilaire et al. JOURNAL OF CONTROLLED RELEASE
- Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery
- (2019) S. Rahima Benhabbour et al. Nature Communications
- LB8. Microarray Patch Delivery of Long-Acting HIV PrEP and Contraception
- (2019) Annie Rein-Weston et al. Open Forum Infectious Diseases
- Long-acting injectable therapy
- (2019) Ronald D’Amico et al. Current Opinion in HIV and AIDS
- Long-acting implants to treat and prevent HIV infection
- (2019) Ethel D. Weld et al. Current Opinion in HIV and AIDS
- Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1
- (2019) Martin Markowitz et al. Current Opinion in HIV and AIDS
- Long-acting injectable cabotegravir for the prevention of HIV infection
- (2019) Meredith E. Clement et al. Current Opinion in HIV and AIDS
- Polypharmacy, Drug–Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV
- (2019) Perrine Courlet et al. Open Forum Infectious Diseases
- Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles
- (2018) Tian Zhou et al. BIOMATERIALS
- Ibalizumab: First Global Approval
- (2018) Anthony Markham DRUGS
- Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies
- (2018) Josep M Llibre et al. LANCET
- Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals
- (2018) Tian Zhou et al. Nanomedicine
- Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women
- (2018) Andrea Ries Thurman et al. PLoS One
- Rilpivirine long-acting for the prevention and treatment of HIV infection
- (2018) Francesca Ferretti et al. Current Opinion in HIV and AIDS
- Antiretroviral implants for treatment and prevention of HIV infection
- (2018) Charles Flexner Current Opinion in HIV and AIDS
- Treatment and prevention of HIV infection with long-acting antiretrovirals
- (2018) Laura Benítez-Gutiérrez et al. Expert Review of Clinical Pharmacology
- Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis
- (2018) Corrine Ying Xuan Chua et al. JOURNAL OF CONTROLLED RELEASE
- Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1
- (2018) Brinda Emu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Acting HIV Drugs for Treatment and Prevention
- (2018) Roy M. Gulick et al. Annual Review of Medicine
- Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor
- (2018) Dario Cattaneo et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension
- (2018) Maelíosa T.C. Mc Crudden et al. JOURNAL OF CONTROLLED RELEASE
- Ultra-long-acting removable drug delivery system for HIV treatment and prevention
- (2018) Martina Kovarova et al. Nature Communications
- Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis
- (2018) Charles Flexner et al. Current Opinion in HIV and AIDS
- Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
- (2017) David A Margolis et al. LANCET
- Long-acting injectable ART: next revolution in HIV?
- (2017) Mark A Boyd et al. LANCET
- Long-Acting Antiretrovirals: Where Are We now?
- (2017) Amesika N Nyaku et al. Current HIV/AIDS Reports
- Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
- (2017) Martin Markowitz et al. Lancet HIV
- Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy
- (2016) Andrew Owen et al. ADVANCED DRUG DELIVERY REVIEWS
- Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals
- (2016) Manel Aouri et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women
- (2016) Annalene Nel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women
- (2016) Jared M. Baeten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients
- (2016) Baralee Punyawudho et al. Expert Review of Clinical Pharmacology
- Pharmacokinetics of Long-Acting Tenofovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis
- (2015) Manjula Gunawardana et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial
- (2015) David A Margolis et al. LANCET INFECTIOUS DISEASES
- Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment fromin vitrostudies and a clinical investigation with midazolam
- (2015) Melinda J. Reese et al. XENOBIOTICA
- Formulation and pharmacology of long-acting rilpivirine
- (2015) Peter E. Williams et al. Current Opinion in HIV and AIDS
- Formulation and pharmacology of long-acting cabotegravir
- (2015) Christine Trezza et al. Current Opinion in HIV and AIDS
- Adherence to Preexposure Prophylaxis: Current, Emerging, and Anticipated Bases of Evidence
- (2014) K. Rivet Amico et al. CLINICAL INFECTIOUS DISEASES
- A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis
- (2014) A G A Jackson et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacokinetics of the etonogestrel contraceptive implant in obese women
- (2012) Sara Mornar et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Androgens and doping tests: genetic variation and pit-falls
- (2012) Anders Rane et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
- (2012) Jared M. Baeten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men
- (2010) Robert M. Grant et al. NEW ENGLAND JOURNAL OF MEDICINE
- TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1
- (2009) H. Azijn et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More